Olon Group Names Jérôme Bédier CEO of French Entities

• Olon Group has appointed Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech.

Olon Group, a global pharmaceutical CDMO, has announced two key leadership appointments aimed at strengthening its biologics and complex molecule manufacturing services. Jérôme Bédier has been named CEO of Olon’s French entities, while Andrea Conforto will serve as M&S VP CDMO of Olon Biotech, the company’s biologics-focused division.

The appointments are part of Olon’s ongoing strategy to expand its capabilities in Antibody-Drug Conjugates (ADCs), Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and microbial bioproduction. Bédier will oversee the integration of French CDMO operations into Olon Group and advance the company’s biopharmaceutical offerings. He succeeds Alain Sainsot, the former head of GTP Bioways, which Olon recently acquired.

Conforto will lead strategic business development for Olon Biotech across Europe, North America, and Asia, focusing on building partnerships with biotech and pharmaceutical companies.

The move also supports Olon’s broader push to offer a fully integrated ADC solution—from Cell Line Development (CLD) to drug product manufacturing—including payload and linker production. The company is concurrently leveraging recent investments in its Rodano site in Italy, boosting HPAPI production capacity.

Maurizio Sartorato, VP Biotech BU at Olon Group, stated: “Strengthening our leadership in bioproduction requires a global and integrated vision. With Jérôme and Andrea, we are reinforcing our expertise to address the growing needs of the ADC, HPAPI, and microbial bioproduction markets.”